<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport"
	content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca Oncology">
<link rel="stylesheet" href="css/style.css" />
<link rel="stylesheet" href="css/animate.min.css" />
<style type="text/css">
    .scrollcontainer .content {margin: 0px 20px 20px 121px; width:782px; }
    .scrollcontainer {position: absolute; top: 222px; height: 505px; overflow-y: scroll; }
    .tableheader, .tablefooter, table{color:#666767; font-size:18px; top: 167px; position:relative;line-height: 23px;}
    .tablefooter{top: 207px;}
    table  {width:100%; top: 4px; position:relative;font-size:12px; line-height:15px;}
    td, th, tr:nth-of-type(2)  th:first-of-type { border:1px solid; border-collapse: collapse; padding: 8px 10px 4px;text-align: center;  vertical-align: middle; }
    th {font-family:'HelveticaNeueLTStd-Bd';background:#f6f6f6; } 
    td:first-of-type, th:first-of-type {text-align:left; padding: 8px 5px 4px;}
    th:first-of-type {vertical-align: bottom; }
    .abbrev, .content ol {font-size:12px; line-height:15px; position:relative; color:#666767; top: 15px; margin-bottom:20px;}
    .content ol {list-style: none;counter-reset: listStyle;}
    .content ol li { counter-increment: listStyle; display:inline-block;}
    .content ol li::before { margin-right: 1em; content: counter(listStyle, lower-alpha); display: inline-block; float:left; height:17px;width:10px;}
    ::-webkit-scrollbar { width: 25px; margin-top:50px;}
    ::-webkit-scrollbar-track {  border:2px solid #d6d5d3; background:#ffffff; border-radius: 15px; margin:2px;}
    ::-webkit-scrollbar-thumb {  background-color: #0cc6dd; border: 4px solid transparent; border-radius: 15px;  background-clip: content-box;}
    
</style>
</head>
<body class='nolvadex'>
	<div class='container'>
        <div class="content">
	       <h1>Nolvadex Safety &amp; Tolerability<sup>1</sup></h1>
           <div class="tableheader">Summary of serious adverse events from the primary risk reduction trials<sup>1</sup></div>
		</div>
	    <div class="scrollcontainer scrollable" >
	       <div class="content" style="min-height: 101%;">
           <table>
            <tr>
                <th rowspan="2">Risk factor</th>
                <th colspan="2">Cuzick meta-analysis<sup>a</sup></th>
                <th colspan="2">IBIS-I<sup>b</sup></th>
                <th colspan="2">NSABP P1<sup>c</sup></th>
                <th colspan="2">Royal Marsden<sup>d</sup></th>
            </tr>
            <tr>
                <th>Tamox<br/>n=14,192</th>
                <th>Placebo<br/>n=14,214</th>
                <th>Tamox<br/>n=3,579</th>
                <th>Placebo<br/>n=3,575</th>
                <th>Tamox<br/>n=6,597</th>
                <th>Placebo<br/>n=6,610</th>
                <th>Tamox<br/>n=1,238</th>
                <th>Placebo<br/>n=1,233</th>
            </tr>
            <!--  -->
            <tr>
                <td>All-cause mortality</td>
                <td>214 (1.5%)</td>
                <td>218 (1.5%)</td>
                <td>182 (5.1%)</td>
                <td>166 (4.6%)</td>
                <td>126 (1.9%)</td>
                <td>114 (1.7%)</td>
                <td>54 (4.4%)</td>
                <td>54 (4.4%)</td>
            </tr>
            <tr>
                <td>Endometrial cancer</td>
                <td>67 (0.6%)</td>
                <td>31 (0.3%)</td>
                <td>29 (0.81%)</td>
                <td>20 (0.56%)</td>
                <td>53 (0.8%)</td>
                <td>17 (0.3%)</td>
                <td>13 (1.1%)</td>
                <td>5 (0.41%)</td>
            </tr>
            <tr>
                <td>Other cancers</td>
                <td>372 (2.6%)</td>
                <td>367 (2.6%)</td>
                <td>351 (9.8%)</td>
                <td>315 (8.8%)</td>
                <td>178 (2.7%)</td>
                <td>155 (2.3%)</td>
                <td>64 (5.2%)</td>
                <td>70 (5.7%)</td>
            </tr>
             <tr>
                <td>Deep vein thrombosis</td>
                <td rowspan="2">131 (1.0%)</td>
                <td rowspan="2">82 (0.6%)</td>
                <td>50 (1.4%)</td>
                <td>29 (0.81%)</td>
                <td>49 (0.74%)</td>
                <td>34 (0.51)</td>
                <td rowspan="2">13 (1.1%)</td>
                <td rowspan="2">9 (0.73%)</td>
            </tr>
            <tr>
                <td>Pulmonary embolism</td>
                <td>30 (0.84%)</td>
                <td>22 (0.62%)</td>
                <td>28 (0.42%)</td>
                <td>13 (0.20%)</td>
            </tr>
            <tr>
                <td>Stroke</td>
                <td>NR</td>
                <td>NR</td>
                <td>30 (0.84%)</td>
                <td>28 (0.78%)</td>
                <td>71 (1.1%)</td>
                <td>50 (0.76%)</td>
                <td>10 (0.81%)</td>
                <td>16 (1.3%)</td>
            </tr>
            <tr>
                <td>Transient ischaemic<br/>attack</td>
                <td>NR</td>
                <td>NR</td>
                <td>NR</td>
                <td>NR</td>
                <td>31 (0.47%)</td>
                <td>34 (0.51%)</td>
                <td>NR</td>
                <td>NR</td>
            </tr>
            <tr>
                <td>Ischaemic<br/>
heart disease/<br/>
cardiovascular events</td>
                <td>144 (1.1%)</td>
                <td>130 (1.0%)</td>
                <td>141 (3.9%)</td>
                <td>153 (4.3%)</td>
                <td>113 (1.7%)</td>
                <td>109 (1.6%)</td>
                <td>21 (1.7%)</td>
                <td>26 (2.1%)</td>
            </tr>
            <tr>
                <td>Myocardial infarction</td>
                <td>NR</td>
                <td>NR</td>
                <td>13 (0.36%)</td>
                <td>17 (0.48%)</td>
                <td>43 (0.65%)</td>
                <td>44 (0.67%)</td>
                <td>NR</td>
                <td>NR</td>
            </tr>
            <tr>
                <td>Cataracts</td>
                <td>654 (6.4%)</td>
                <td>583 (5.7%)</td>
                <td>67 (1.9%)<sup>e</sup></td>
                <td>54 (1.5%)<sup>e</sup></td>
                <td>574 (9.4%)<sup>f</sup></td>
                <td>507 (8.3%)<sup>f</sup></td>
                <td>12 (0.97)</td>
                <td>3 (0.24%)</td>
            </tr>
            <tr>
                <td>Fractures</td>
                <td>731 (7.2%)</td>
                <td>791 (7.8%)</td>
                <td>240 (6.7%)<sup>e</sup></td>
                <td>235 (6.6%)<sup>e</sup></td>
                <td>80 (1.2%)</td>
                <td>116 (1.8%)</td>
                <td>28 (2.3%)</td>
                <td>33 (2.7%)</td>
            </tr>
           </table>
           
           <span class="abbrev">Abbreviations: NR = not reported, tamox = tamoxifen.</span>
           <ol>
           <li>Cuzick 2013<sup>2</sup> was a meta-analysis of individual participant data from the IBIS-I, NSABP P1, and Royal Marsden primary risk reduction trials
in women at increased risk of breast cancer, and the Italian trial in women at normal risk of breast cancer. The median follow up was 65 months.</li>
           <li>Women aged 35-70 at increased risk of breast cancer were treated with 20 mg tamoxifen for 5 years; the median follow up was 16 years.</li>
           <li>Women aged 35+ with a breast cancer risk â‰¥ 1.66% over next 5 years were treated with 20 mg tamoxifen for 5 years; the median follow up was<br/>
6 years</li>
           <li>Women aged 30-70 with a family history of breast cancer were treated with 20 mg tamoxifen for 8 years; the median follow up was 13 years</li>
           <li>Results from earlier analysis; median follow up was 8 years</li>
           <li>Results from earlier analysis; n=6,101 tamoxifen and 6,131 placebo; the median follow up was 4 years.</li> 
           </ol>
           <span class="abbrev">&nbsp;</span>
           </div>
           </div>
		<span class='logo'></span>
		<div class="glasspane"></div>
		<div class="popup">
			<div class='ref'>
				<p>Reference:</p>
				<ol>
					<li>Nolvadex Approved Product<br />Information. April 2016.</li>
					<li>Cuzick J et al. <i>Lancet.</i><br />
2013;381:1827-34</li>
				</ol>
			</div>
			
		</div>
		<div class='footer'></div> 
		<div class="controls">
            <span class="r"></span>
            <span class="i disabled"></span>
            <span class="p"></span>
        </div>
	</div>
	<script type="text/javascript">
       var idx = 'N04';
    </script>
    <script src="js/jquery-3.1.1.min.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/touchy.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/script.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/variables.js" type="text/javascript" charset="utf-8"></script>
</body>
</html>
